All articles tagged with #cobenfy
Bristol Myers Squibb bets that Cobenfy, a 30-year-old drug, can become the first approved treatment for psychosis in Alzheimer's disease; its fate hinges on three pivotal trials later this year after a long-ago trial showed promise but was marred by adverse effects, a rescue journey from Eli Lilly to Karuna Therapeutics before landing with BMS.
Bristol Myers Squibb's stock rose over 5% after delaying the results of a clinical trial for Cobenfy, a drug for Alzheimer's disease psychosis, due to enrollment irregularities. The delay, expected to extend the trial completion to 2026, suggests positive trends despite concerns, and the stock's movement reflects investor optimism about the potential market and ongoing development efforts.
A study analyzing real-world data suggests that the new schizophrenia drug Cobenfy is most effective for patients with negative symptoms like social withdrawal, supporting the move toward precision psychiatry by identifying biological subtypes of psychosis that respond differently to treatment.